Forgot your username or password?
Recover it here
Not a member yet?
Register
Agoracom
The Small Cap Epicenter
The Small Cap Epicenter
AGORACOM WIRE .... TUESDAY FEBRUARY 14TH
UPDATE 1:30PM
Graphite Investment Conference Vancouver
Breaking News ....
Strike Graphite Corp. (TSXV:SRK) Acquires Wagon Graphite Project in Quebec in Vicinity of Timcal's Lac des Iles Graphite Mine *CLIENT Read More | Profile
McLaren Resources (CNSX:MCL) Drills 7.0 Grams Gold Over 7.4 Metres at the TimGinn Property Located Adjacent to the Hollinger Mine *CLIENT* Read More | Watch Beyond the Press Release
AGORACOM Launches GraphiteStocksBlog.com
We're proud to announce the launch of GraphiteStocksBlog.com a website dedicated to the needs of investors and companies in the fast growing Graphite industry.
INAUGURAL GRAPHITE SPONSORS
United Therapeutics will make an upfront payment of $7 million to Pluristem; and other payments accumulating together with the upfront payment to a total of approximately $55 million.
United Therapeutics will make an upfront payment of $7 million to Pluristem; and other payments accumulating together with the upfront payment to a total of approximately $55 million.
System is designed to creates an artificial physiological environment where cells (ASCs) can grow and reproduce outside of the human body. By mimicking the natural environment that exists within human bones, the system “tricks” stem cells into growing and reproducing in the same way they would in living organs. Because the size and scale of the PluriX™ Bioreactor is larger than that of human bone marrow, stem cell growth can be greatly expanded.
“The results of these trials provide a strong indication of the potential success of commercializing PLX-PAD,” said Zami Aberman, President, Chairman and CEO of Pluristem
Company Awarded a $2.5 Million Grant from Israeli Government.
Chaya Mazouz, the company’s vice president of clinical and regulatory affairs, will present information about the regulatory study design considerations for PLX-PAD, the company’s lead cell therapy candidate for the treatment of critical limb ischemia (CLI), at 11 a.m. EDT on May 24 at the International Society for Cellular Therapy’s (ISCT) 16th Annual Meeting in Philadelphia
Data Suggests PLX-PAD is Safe, with Noted Improvement in Measured Efficacy Parameters.
It has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD for the treatment of critical limb ischemia, of (PAD).
The title of the conference was “Stem Cell Therapy – The Future of Medicine” and was held on March 19, 2009 at the Marriot Del Mar Hotel in San Diego, California. Dr. Prather presented an overview of Pluristem and an update on the clinical development of the Company’s placental-derived (PLX) stem cells.
Like Pluristem Life Systems, Inc.? Then you might also be interested in Star Navigation Systems Group Ltd.
